Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline for Cognitive Dysfunction in Schizophrenia
NCT00523445Phase 3Completed
- Sponsor
- Inje University
- Start
- Sep 2007
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Varenicline with Placebo (2 arms). Primary endpoint: Neurocognitive function at 8 weeks. Started Sep 2007; status: completed.
02
Drugs
varenicline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00523445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00523445.